|
|
|
| The Influence of Glutaraldehyde Polymerization on Immunological Properties of Porcine Hemoglobin, Bovine Hemoglobin and Human Hemoglobin |
| ZHU Xiao-li1, WANG Tong-wen2 |
1. Northwest University Shaanxi R&D Center of Biomaterials and Fermentation Engineering, Xi'an 710127, China;
2. Northwest University National Engineering Research Center for Miniaturized Detection System, Xi'an 710127, China |
|
|
|
Abstract To reveal the effects of glutaraldehyde polymerization on the immunological properties of porcine hemoglobin, bovine hemoglobin and human hemoglobin, repeated ip. or sc. administration of an immunizing dose of pHb, bHb, hHb or their glutaraldehyde cross-linked derivatives were given to mice to stimulate IgG responses, which was measured by indirect ELISA. Western blotting analysis of the antibody-antigen cross-binding reations between pHb, bHb, hHb or its related glutaraldehyde polymerized hemoglobin derivatives and anti-hemoglobin or anti-glutaraldehyde polymerized hemoglobin antibodies raised in mice were used in order to investigate the effects of glutaraldehyde polymerization on the immunological properties of the proteins concerned.The results indicated that hHb, bHb and pHb are all weakly immunogenic, while polymerization significantly increases the immunogenicity of all their glutaraldehyde-cross-linked derivatives. There exist clear species-specific antigen-determinants in hHb, bHb and pHb. The effects of glutaraldehyde polymerization on immunological properties of porcine hemoglobin, bovine hemoglobin and human hemoglobin are significantly different, there were no neo-antigens formed in pPolyHb, some of the determinants of bHb were covered because of glutaraldehyde polymerization, however,neo-antigens produced in hPolyHb. Therefore,it is necessary to study the immunological characteristics of different HBOCs products separately and should not inferred the characteristics of the products from different kinds of Hb even when they were made by the same method.
|
|
Received: 25 February 2011
Published: 28 June 2011
|
|
|
|
Corresponding Authors:
zhu xiaoli
E-mail: zhuxiaoli1369@163.com
|
|
|
| [1] Paul M N, Melissa M C. Oxygen therapeutics pursuit of an alternative to the donor red blood cell. Arch Pathol Lab Med, 2007, 131:734-741.
[2] Moore E E, Moore F A, Fabian T C, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multi-center trial. J Am Coll Surg, 2009, 208:1-13.
[3] Chen J Y, Michelle S, George K. A review of blood substitutes: examining the history, clinical trial results and ethics of hemoglobin-based oxygen carriers. Clinics, 2009, 64(8):803-813.
[4] Chang T M. Hemoglobin-based red blood cell substitutes. Artificial Organs,2004, 28 (9):789-794.
[5] Nelson D, Azari M, Brown R, et al. Preparation and characterization of diaspirin cross-linked hemoglobin solutions for preclinical studies. Biomat Artif Cell Im, 1992, 20: 423-427.
[6] Hsia J C. O-raffinose polymerized hemoglobin as a red cell substitute. Biomat Artif Cell Im,1991,19:401.
[7] Sehgal L R, Gould S A, Rosen A L, et al. Polymerized pyridoxalated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery, 1984, 95: 433-438.
[8] Vandegriff K D, Malavalli A, Wooldrige J, et al. MP4, a new nonvasoactive PEG-Hb conjugate.Transfusion,2003,43:509-516.
[9] Bleeker W K, Zappeij L M, den Boer P J.Evaluation of the immunogenicity of polymerized hemoglobin solutions in a rabbit model. Artif Cells Blood Substit Immobil Biotechnol,1995, 23(4):461-468.
[10] Mehul J P, Edwin J W, Tina E S, et al. Absence of immunogenicity of Diaspirin cross-linked hemoglobin in humans.Blood,1998,191:710-716.
[11] Hertzman C M, Keipert P E, Chang T M. Serum antibody titers in rats receiving repeated small subcutaneous injections of hemoglobin or polyhemoglobin: a preliminary report. Int J Artif Organs,1986, 9(3):179-182.
[12] Chang T M, Lister C, Nishiya V R, et al. Immunological effects of hemoglobin, encapsulated hemoglobin, polyhemoglobin and conjugated hemoglobin using different immunization schedules. Biomater Artif Cells Immobilization Biotechnol, 1992,20(2-4):611-618.
[13] Schubert A, Przybelski R J, Eidt J F, et al. Diaspirin cross-linked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial. Anesth Analg, 2003,97:323-332.
[14] Estep T N, Gonder J, Bornstein I, et al. Immunogenicity of diaspirin cross-linked human hemoglobin solutions. Biomater Artif Cells Immobilization Biotechnol, 1992, 20(2-4): 603-609.
[15] 王军志.生物技术药物研究开发和质量控制. 北京:科学出版社,2002.721. Wang J Z. Research Development and Quality Control of Biotechnological Pharmaceutics. Science Press, 2002, 721.
[16] 朱晓丽. 戊二醛聚合猪血红蛋白氧载体免疫学特性及其作用机理的研究. 西安:西北大学,化工学院,2007. Zhu X L. The study of imunological properties and mechanisms of glutaraldehyde polymerized/modified porcine hemoglobin oxygen carrier. Xi'an: Northwest University, School of Chemical Engineering, 2007.
[17] Natanson C, Kern S J, Lurie P, et al. Cell free Hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA, 2008,299:2304-2312.
[18] Darin S K, Steven P W, Huang W, et al. Structure determination of aquomet porcine hemoglobin at 2.8A resolution. J Mol Biol, 1994, 244: 541-553. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
